Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice
mBio · 14.02.2024 · 15 (2)
DOI: 10.1128/mbio.02554-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 14.02.2024. Verfasst von Anne L Rosen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Anti-Infective Agents, Cystitis, Escherichia coli Infections, Urinary Tract Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Doris Duke Charitable Foundation, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Annually, millions of people suffer from urinary tract infections (UTIs) and more than $3 billion are spent on work absences and treatment of these patients. While the early response to UTI is known to be important in combating urinary pathogens, knowledge of host factors that help curb infection is still limited. Here, we use a preclinical model of UTI to study secretory leukocyte protease inhibitor (SLPI), an antimicrobial protein, to determine how it protects the bladder against infection. We find that SLPI is increased during UTI, accelerates the clearance of bacteriuria, and upregulates genes and pathways needed to fight an infection while preventing prolonged bladder inflammation. In a small clinical study, we show SLPI is readily detectable in human urine and is associated with the presence of a uropathogen in patients without a previous history of UTI, suggesting SLPI may play an important role in protecting from bacterial cystitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Infectious Diseases, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Anne L Rosen, Nicole M Gilbert, Carey-Ann D Burnham, Andrew L Kau
Förderung
- Doris Duke Charitable Foundation
- NIAID NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Rosen, A. L., Lint, M. A., Voelker, D. H., Gilbert, N. M., Tomera, C. P., Santiago-Borges, J., Wallace, M. A., Hannan, T. J., Burnham, C. A. D., Hultgren, S. J., & Kau, A. L. (2024). Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice. mBio, 15(2). https://doi.org/10.1128/mbio.02554-23
Vancouver
Rosen AL, Lint MA, Voelker DH, Gilbert NM, Tomera CP, Santiago-Borges J, et al. Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice. mBio. 2024;15(2). doi:10.1128/mbio.02554-23
BibTeX
@article{Rosen2024,
author = {Rosen, Anne L and Lint, Michael A and Voelker, Dayne H and Gilbert, Nicole M and Tomera, Christopher P and Santiago-Borges, Jesús and Wallace, Meghan A and Hannan, Thomas J and Burnham, Carey-Ann D and Hultgren, Scott J and Kau, Andrew L},
title = {Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice},
journal = {mBio},
year = {2024},
volume = {15},
number = {2},
doi = {10.1128/mbio.02554-23}
}
EUVIMED